BRPI1014821A2 - "inibidores de replicação de hiv" - Google Patents
"inibidores de replicação de hiv"Info
- Publication number
- BRPI1014821A2 BRPI1014821A2 BRPI1014821A BRPI1014821A BRPI1014821A2 BR PI1014821 A2 BRPI1014821 A2 BR PI1014821A2 BR PI1014821 A BRPI1014821 A BR PI1014821A BR PI1014821 A BRPI1014821 A BR PI1014821A BR PI1014821 A2 BRPI1014821 A2 BR PI1014821A2
- Authority
- BR
- Brazil
- Prior art keywords
- hiv replication
- replication inhibitors
- inhibitors
- hiv
- replication
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16803209P | 2009-04-09 | 2009-04-09 | |
US26368909P | 2009-11-23 | 2009-11-23 | |
PCT/CA2010/000478 WO2010115264A1 (en) | 2009-04-09 | 2010-04-07 | Inhibitors of hiv replication |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI1014821A2 true BRPI1014821A2 (pt) | 2016-04-05 |
Family
ID=42934876
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI1014821A BRPI1014821A2 (pt) | 2009-04-09 | 2010-04-07 | "inibidores de replicação de hiv" |
Country Status (15)
Country | Link |
---|---|
US (1) | US8349839B2 (pt) |
EP (1) | EP2417140B1 (pt) |
JP (1) | JP5643290B2 (pt) |
KR (1) | KR20120034592A (pt) |
CN (1) | CN102388051A (pt) |
AR (1) | AR076252A1 (pt) |
AU (1) | AU2010234241A1 (pt) |
BR (1) | BRPI1014821A2 (pt) |
CA (1) | CA2758149A1 (pt) |
CL (1) | CL2011002258A1 (pt) |
EA (1) | EA201101397A1 (pt) |
IL (1) | IL214606A0 (pt) |
MX (1) | MX2011010582A (pt) |
TW (1) | TW201103940A (pt) |
WO (1) | WO2010115264A1 (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9399645B2 (en) * | 2011-12-20 | 2016-07-26 | Boehringer Ingelheim International Gmbh | Inhibitors of HIV replication |
EP3233797B1 (en) * | 2015-01-18 | 2019-05-08 | SRI International Inc. | Map4k4 (hgk) inhibitors |
MX2020003488A (es) | 2015-02-02 | 2022-05-24 | Forma Therapeutics Inc | Acidos 3-alquil-4-amido-biciclico [4,5,0] hidroxamicos como inhibidores de histona desacetilasas (hdac). |
AR103598A1 (es) | 2015-02-02 | 2017-05-24 | Forma Therapeutics Inc | Ácidos bicíclicos[4,6,0]hidroxámicos como inhibidores de hdac |
EP3472131B1 (en) | 2016-06-17 | 2020-02-19 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors |
US11667651B2 (en) | 2017-12-22 | 2023-06-06 | Hibercell, Inc. | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
WO2020028482A1 (en) * | 2018-07-31 | 2020-02-06 | The Trustees Of The University Of Pennsylvania | Small molecules that sensitize hiv-1 infected cells to antibody dependent cellular cytotoxicity |
CN111560022A (zh) * | 2020-05-13 | 2020-08-21 | 深圳职业技术学院 | 四氢苯并呋喃[3,2-d]嘧啶类衍生物及其制备方法及应用 |
CN116332947A (zh) * | 2021-12-24 | 2023-06-27 | 上海海和药物研究开发股份有限公司 | 具有mat2a抑制活性的嘧啶-2(1h)-酮并二环类化合物及其用途 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8016A (en) * | 1851-04-01 | Improvement in the manufacture of india-rubber | ||
JPH06172365A (ja) * | 1992-12-11 | 1994-06-21 | Yamasa Shoyu Co Ltd | 10−チアイソアロキサジン誘導体およびその用途 |
JPH06220059A (ja) * | 1993-01-28 | 1994-08-09 | Tanabe Seiyaku Co Ltd | 縮合ピリミジン誘導体及びその製法 |
US6593337B1 (en) * | 1999-10-19 | 2003-07-15 | Bristol-Myers Squibb Pharma Company | Tricyclic compounds useful as HIV reverse transcriptase inhibitors |
EP1209158A1 (en) | 2000-11-18 | 2002-05-29 | Aventis Pharma Deutschland GmbH | Substituted beta-carbolines |
TWI270547B (en) * | 2000-06-16 | 2007-01-11 | Boehringer Ingelheim Ca Ltd | Non-nucleoside reverse transcriptase inhibitors |
WO2003099206A2 (en) | 2002-05-21 | 2003-12-04 | Bristol-Myers Squibb Company | Indole compounds useful as impdh inhibitors |
US20030139427A1 (en) * | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
WO2004046163A1 (ja) | 2002-11-08 | 2004-06-03 | Kaneka Corporation | エルゴステロールの分離方法 |
KR20050084621A (ko) | 2002-11-15 | 2005-08-26 | 티보텍 파마슈티칼즈 리미티드 | 항감염성 화합물로서의 치환된 인돌피리디늄 |
US7642277B2 (en) | 2002-12-04 | 2010-01-05 | Boehringer Ingelheim International Gmbh | Non-nucleoside reverse transcriptase inhibitors |
WO2004096807A2 (en) * | 2003-04-28 | 2004-11-11 | Tibotec Pharmaceuticals Ltd. | Hiv integrase inhibitors |
US20060074124A1 (en) * | 2003-09-12 | 2006-04-06 | Andrew Napper | Methods of treating a disorder |
JP2007509149A (ja) * | 2003-10-20 | 2007-04-12 | メルク エンド カムパニー インコーポレーテッド | Hivインテグラーゼ阻害薬として有用なヒドロキシピリドピロロピラジンジオン化合物 |
WO2005076861A2 (en) * | 2004-02-04 | 2005-08-25 | University Of Virginia Patent Foundation | Compounds that inhibit hiv particle formation |
AR049340A1 (es) | 2004-05-17 | 2006-07-19 | Tibotec Pharm Ltd | 1- heterociclil - l, 5- dihidro- pirido (3,2-b) indol - 2- onas |
ES2351702T3 (es) | 2004-05-17 | 2011-02-09 | Tibotec Pharmaceuticals | 1-fenil-1,5-dihidro-pirido[3,2-b]indol-2-onas 6,7,8,9-sustituidas útiles como agentes farmacéuticos antiinfecciosos. |
CN1953978B (zh) | 2004-05-17 | 2010-09-29 | 泰博特克药品有限公司 | 作为抗病毒剂的5-取代的1-苯基-1,5-二氢-吡啶并[3,2-b]吲哚-2-酮及其类似物 |
EA200602136A1 (ru) * | 2004-05-17 | 2007-04-27 | Тиботек Фармасьютикалз Лтд. | Комбинации замещенных 1-фенил-1,5-дигидропиридо[3,2-b] индол-2-онов и других ингибиторов вич |
TW200613307A (en) * | 2004-05-17 | 2006-05-01 | Tibotec Pharm Ltd | 4-substituted-1,5-dihydro-pyrido[3,2-b]indol-2-ones |
EP1773840B1 (de) * | 2004-07-23 | 2010-01-20 | The Medicines Company (Leipzig) GmbH | Substituierte pyrido[3',2':4,5]thieno[3,2-d]pyrimidine und pyrido[3',2':4,5]furo[3,2-d]-pyrimidine zur verwendung als inhibitoren der pda-4 und/oder tnf-alpha freisetzung |
DE602005025900D1 (de) | 2004-09-30 | 2011-02-24 | Boehringer Ingelheim Pharma | Alkynilbasierte derivate von benzophenonen als nichtnukleoside reverse-transkriptase-inhibitoren |
JP2008515982A (ja) | 2004-10-13 | 2008-05-15 | メルク エンド カムパニー インコーポレーテッド | 高眼圧症を治療するための眼科組成物 |
BRPI0517211B8 (pt) | 2004-12-17 | 2021-05-25 | Glenmark Pharmaceuticals Sa | composto, composição farmacêutica e seu uso. |
US20060276440A1 (en) | 2005-01-03 | 2006-12-07 | An Wenqian F | Treatment of inflammatory disorders |
US20070049591A1 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
WO2007088214A2 (en) * | 2006-02-03 | 2007-08-09 | Tibotec Pharmaceuticals Ltd. | Treating hiv infection, wherein hiv has a k65r mutation |
WO2008037783A1 (en) | 2006-09-29 | 2008-04-03 | Tibotec Pharmaceuticals Ltd. | Process for preparing 2-oxo-2,5-dihydro-1h-pyrido[3,2-b]indole-3-carbonitriles |
DE102006062203A1 (de) * | 2006-12-22 | 2008-06-26 | Curacyte Discovery Gmbh | Substituierte 5H-Pyrimido[5,4-b]indole als Induktoren der Apoptose bei B-CLL Zellen |
SI2125792T1 (sl) | 2007-02-19 | 2011-03-31 | Glaxosmithkline Llc | Purinski derivati kot imunomodulatorji |
WO2008119070A1 (en) | 2007-03-28 | 2008-10-02 | Trustees Of Boston University | Methods of treatment using sirt modulators and compositions containing sirt1 modulators |
EA201001030A1 (ru) | 2007-12-19 | 2011-02-28 | Амген Инк. | Конденсированные соединения пиридина, пиримидина и триазина в качестве ингибиторов клеточного цикла |
-
2010
- 2010-04-07 JP JP2012503835A patent/JP5643290B2/ja active Active
- 2010-04-07 EP EP10761139.4A patent/EP2417140B1/en active Active
- 2010-04-07 KR KR1020117023696A patent/KR20120034592A/ko not_active Application Discontinuation
- 2010-04-07 MX MX2011010582A patent/MX2011010582A/es unknown
- 2010-04-07 WO PCT/CA2010/000478 patent/WO2010115264A1/en active Application Filing
- 2010-04-07 CA CA2758149A patent/CA2758149A1/en not_active Abandoned
- 2010-04-07 EA EA201101397A patent/EA201101397A1/ru unknown
- 2010-04-07 CN CN2010800156236A patent/CN102388051A/zh active Pending
- 2010-04-07 BR BRPI1014821A patent/BRPI1014821A2/pt not_active Application Discontinuation
- 2010-04-07 AU AU2010234241A patent/AU2010234241A1/en not_active Abandoned
- 2010-04-08 TW TW099110936A patent/TW201103940A/zh unknown
- 2010-04-08 US US12/756,276 patent/US8349839B2/en active Active
- 2010-04-08 AR ARP100101202A patent/AR076252A1/es unknown
-
2011
- 2011-08-11 IL IL214606A patent/IL214606A0/en unknown
- 2011-09-12 CL CL2011002258A patent/CL2011002258A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP2417140A4 (en) | 2013-02-20 |
TW201103940A (en) | 2011-02-01 |
EP2417140A1 (en) | 2012-02-15 |
US20100261714A1 (en) | 2010-10-14 |
JP5643290B2 (ja) | 2014-12-17 |
EA201101397A1 (ru) | 2012-05-30 |
WO2010115264A1 (en) | 2010-10-14 |
CN102388051A (zh) | 2012-03-21 |
MX2011010582A (es) | 2011-10-19 |
AU2010234241A1 (en) | 2011-09-08 |
KR20120034592A (ko) | 2012-04-12 |
JP2012523380A (ja) | 2012-10-04 |
IL214606A0 (en) | 2011-09-27 |
EP2417140B1 (en) | 2014-11-26 |
CA2758149A1 (en) | 2010-10-14 |
AR076252A1 (es) | 2011-05-26 |
CL2011002258A1 (es) | 2012-02-10 |
US8349839B2 (en) | 2013-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY2018030I1 (el) | Φαρμακοτεχνικη μορφη 514 | |
FR16C1026I2 (fr) | Inhibiteurs de la replication du virus de l'hepatite c | |
BRPI0910307A2 (pt) | inibidores de hiv integrase | |
BR112012012872A2 (pt) | "pirrolindinas de espiroindolinona" | |
BR112012014254A2 (pt) | "artigo de múltiplas camadas" | |
CR10693A (es) | Enantiomerically pure phosphoindoles as hiv inhibitors | |
BRPI1009315A2 (pt) | agentes anti-inflamatórios | |
BRPI1012004A2 (pt) | "forma farmacêutica" | |
BRPI1014956A2 (pt) | agentes antinflamatórios. | |
BR112012003780A2 (pt) | pregão semântico | |
BRPI0920521A2 (pt) | combinação farmacêutica | |
DK3097925T3 (da) | Farmaceutisk sammensætning | |
BRPI1004940A2 (pt) | composição farmacêutica | |
BR112012010595A2 (pt) | "dispensdor" | |
BR112012004593A2 (pt) | "método" | |
BRPI1014821A2 (pt) | "inibidores de replicação de hiv" | |
BRPI1015939A2 (pt) | composição farmacêutica | |
FR2944062B1 (fr) | Injecteur d'ergols | |
BR112012003149A2 (pt) | composição farmacêutica | |
BRPI1006361A2 (pt) | "artigo absorvente" | |
BRPI1006474A2 (pt) | "gatilho" | |
FIU20090470U0 (fi) | Aukirullain | |
IT1399458B1 (it) | "mandrino" | |
BRPI1013017A2 (pt) | "17beta-alquil-17alfa-óxi-estratrienos" | |
FR2953502B1 (fr) | Table d'accumulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |